Randomized trial · people

Retatrutide: less hunger and overeating vs placebo at higher doses

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In adults with type 2 diabetes, the higher retatrutide doses in this trial went along with less reported hunger and overeating, and people who reported these changes tended to lose more weight.

Kind
Randomized trial
Studied in
People
Number studied
275
Published
2025
Journal
Diabetes Obes Metab

What they tested

The team wanted to know whether retatrutide changes self-reported appetite and eating behavior in adults with type 2 diabetes more than placebo or dulaglutide, and whether those changes track with weight loss.

How the study was done

This was a planned exploratory look at a randomized, placebo-controlled phase 2 trial in 275 adults with type 2 diabetes. Each week for up to 36 weeks, people received one of four retatrutide doses (from 0.5 mg up to 12 mg), dulaglutide at 1.5 mg, or placebo (a dummy treatment), and they filled in two questionnaires on appetite and eating habits.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 24, people in the retatrutide 4 mg and higher arms reported bigger drops in overall appetite, hunger and how much food they expected to eat than the placebo group (all p <0.05). The 8 and 12 mg arms showed greater improvement than placebo in perceived hunger and disinhibition (the tendency to overeat) at both weeks 24 and 36. Dietary restraint, meaning conscious efforts to limit eating, rose more than with placebo only in the 12 mg arm at week 36. At week 36, less perceived hunger, less disinhibition and more dietary restraint each went along with more weight loss (r = 0.28, r = 0.36 and r = 0.31).

What it doesn’t show

These were exploratory questionnaire results based on what participants reported themselves, and the links to weight loss came from post hoc correlations, which show an association, not cause. Differences between retatrutide and dulaglutide were less consistent than those against placebo.

The paper

Kanu et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes Obes Metab. 2025.

The compound

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo